TRPA1 and arthritic joint disease: Although auranofin’s clinical effects in suppressing the inflammatory component of RA are attributed to its inhibition of redox enzymes like thioredoxin reductase [145], it is intriguing that this compound also activates TRPA1 (at least in vitro), an effect that would theoretically increase pain and joint degradation given the evidence for its role in arthritis pathogenesis.